Premium
Gene expression analysis of TLR9 in myeloid and lymphocytic leukemias
Author(s) -
Webb Rachel N,
Cruse Julius M,
Lewis Robert
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.898.35
Subject(s) - tlr9 , myeloid leukemia , biology , leukemia , myeloid , flow cytometry , cd3 , population , haematopoiesis , gene , chronic lymphocytic leukemia , gene expression , immunology , immune system , cancer research , microbiology and biotechnology , medicine , genetics , cd8 , stem cell , environmental health , dna methylation
Previous studies by flow cytometry were directed towards determining whether the presence of several Toll‐like receptors (TLR) differed significantly in the context of leukemia compared to their presence in a normal immune system. A statistically significant increase in the expression intensity of TLR9 in CD3+ cells of leukemic samples was detected when compared to normal controls (P<0.001). The aim of the current study is to determine whether this difference at the protein level is due to differential gene expression of TLR9. Reverse transcription and real‐time PCR were performed on fourteen leukemia samples, three normal controls, and one positive control. The leukemia samples included several subtypes of both the myeloid and lymphocytic lineages. Fold changes of TLR9 relative to beta‐actin were determined for each sample and found to range from 1.9–2.3. However, the magnitude of TLR9 gene expression did not seem to coincide with leukemic status. Therefore, further analysis incorporating both a larger population of samples and evaluation of additional signaling molecules is needed to determine whether the upregulation of TLR9 in CD3+ leukemic cells might either be a response to or stimulus for the proliferation and survival of malignant hematopoietic cells.